FORMULARY DECISION
Certolizumab pegol : Cimzia
1155/16 : Treatment of severe, active and progressive RA in adults not previously treated with MTX or other DMARDs.
Search Results
All Content Formulary Only Other ContentWe have found 12 results when searching "Certolizumab pegol"
FORMULARY DECISION
Certolizumab pegol : Cimzia
SMC2132 : Treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy